Castration-resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy

IJU Case Reports

article

Atsuhi Yanase¹  Toru Sugihara¹  Takahiro Akimoto¹  Hirotaka Yokoyama¹  Jun Kamei¹  Akira Fujisaki¹  Satoshi Ando¹  Tameto Naoi⁴  Mitsuya Morita⁴  Tetsuya Fujimura¹ 

[1] Department of Urology, Jichi Medical University;Contribution: Writing - original draft;Contribution: Writing - review & editing;Rehabilitation Center, Jichi Medical University;Contribution: Conceptualization;Contribution: Supervision

关键词: androgen receptor;    leuprorelin acetate;    motor neuron disease;    prostate cancer;    spinal and bulbar muscular atrophy;   

DOI  :  10.1002/iju5.12447

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction We report a prostate cancer case diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy which is a X-linked recessive, lower motor neuron disease. Case presentation A 64-year-old man who had received leuprorelin treatment over 3 years for his spinal and bulbar muscular atrophy presented with an enlarged prostate accompanied by abdominal pain and constipation. An abnormally high serum prostate-specific antigen of 17.7 ng/mL and a low (castration level) serum testosterone level of 0.23 ng/mL were measured. Prostate needle biopsy revealed adenocarcinoma of the prostate. Orchiectomy, darolutamide, and radiation therapy for the prostate were initiated, resulting in a favorable response which was maintained at 12 months of treatment. Conclusion Prostate cancer can occur even when leuprorelin is used for spinal and bulbar muscular atrophy; therefore, checking serum prostate-specific antigen to screen for prostate cancer before leuprorelin administration should be considered.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND